XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Net product revenue$6,189.0 $5,281.1 $18,579.5 $15,762.3 
Collaboration and other revenue (1)
583.8 459.5 1,739.0 1,337.5 
Revenue$6,772.8 $5,740.6 $20,318.5 $17,099.8 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $62.1 million and $136.1 million during the three and nine months ended September 30, 2021, respectively, and $31.5 million and $101.5 million during the three and nine months ended September 30, 2020, respectively.
The following table summarizes revenue by product for the three months ended September 30, 2021 and 2020:
Three Months Ended September 30,
 20212020
U.S.
Outside U.S.Total
U.S.
Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$1,201.4 $398.8 $1,600.1 $791.2 $315.4 $1,106.6 
Humalog® (1)
347.3 279.4 626.7 390.1 266.9 656.9 
Jardiance (2)
221.2 169.2 390.4 163.3 147.5 310.8 
Humulin®
193.4 93.4 286.7 214.0 91.9 305.9 
Basaglar®
114.7 78.1 192.8 178.5 69.7 248.2 
Other Diabetes65.0 112.2 177.4 61.4 93.1 154.6 
Total Diabetes2,143.0 1,131.1 3,274.1 1,798.5 984.5 2,783.0 
Oncology:
Alimta®
297.2 159.8 457.0 291.9 286.1 578.0 
Verzenio®
199.6 135.9 335.5 158.9 75.5 234.4 
Cyramza®
84.8 168.6 253.4 94.5 158.2 252.7 
Erbitux®
114.0 20.3 134.3 122.5 14.0 136.4 
Tyvyt®
— 125.6 125.6 — 84.4 84.4 
Other Oncology35.3 65.1 100.3 14.7 32.7 47.5 
Total Oncology730.9 675.3 1,406.1 682.5 650.9 1,333.4 
Immunology:
Taltz®
422.2 170.9 593.1 326.2 128.3 454.5 
Olumiant® (3)
194.0 212.9 406.9 14.5 147.5 162.0 
Other Immunology— 4.9 4.9 6.1 4.5 10.6 
Total Immunology616.2 388.7 1,004.9 346.8 280.3 627.1 
Neuroscience:
Emgality®
99.9 40.1 140.0 81.4 10.1 91.5 
Cymbalta®
7.0 125.1 132.0 11.1 175.5 186.6 
Zyprexa®
13.0 88.7 101.7 21.2 91.5 112.7 
Other Neuroscience24.7 51.6 76.5 26.7 53.2 79.9 
Total Neuroscience144.6 305.5 450.2 140.4 330.3 470.7 
Other:
COVID-19 Antibodies (4)
215.5 1.6 217.1 — — — 
Forteo®
109.6 91.3 200.9 144.6 122.3 266.9 
Cialis®
(6.5)137.4 130.9 15.1 147.3 162.5 
Other36.3 52.4 88.8 33.5 63.6 97.0 
Total Other354.9 282.7 637.7 193.2 333.2 526.4 
Revenue$3,989.6 $2,783.3 $6,772.8 $3,161.4 $2,579.3 $5,740.6 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA).
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
The following table summarizes revenue by product for the nine months ended September 30, 2021 and 2020:
Nine Months Ended September 30,
 20212020
U.S. Outside U.S.TotalU.S.Outside U.S.Total
Revenue—to unaffiliated customers:
Diabetes:
Trulicity$3,465.7 $1,122.5 $4,588.2 $2,673.2 $892.5 $3,565.7 
Humalog (1)
1,009.0 842.3 1,851.3 1,070.4 837.4 1,907.8 
Jardiance (2)
566.8 492.1 1,058.9 453.0 387.3 840.3 
Humulin633.5 290.3 923.8 642.5 292.7 935.2 
Basaglar423.3 226.8 650.1 638.7 203.7 842.3 
Other Diabetes185.7 302.6 488.3 185.2 254.4 439.6 
Total Diabetes6,284.0 3,276.6 9,560.6 5,663.0 2,868.0 8,530.9 
Oncology:
Alimta911.9 714.7 1,626.6 933.4 743.8 1,677.2 
Verzenio582.1 363.7 945.8 430.0 201.1 631.1 
Cyramza266.3 496.3 762.5 277.6 470.8 748.4 
Erbitux357.7 45.9 403.7 356.1 40.6 396.7 
Tyvyt— 340.2 340.2 — 205.9 205.9 
Other Oncology83.7 169.9 253.6 26.0 118.2 144.2 
Total Oncology2,201.7 2,130.7 4,332.4 2,023.1 1,780.4 3,803.5 
Immunology:
Taltz1,071.6 493.8 1,565.4 942.9 350.3 1,293.2 
Olumiant (3)
236.5 572.6 809.1 39.0 407.7 446.7 
Other Immunology15.2 14.5 29.7 13.2 8.1 21.3 
Total Immunology1,323.3 1,080.9 2,404.2 995.1 766.1 1,761.2 
Neuroscience:
Cymbalta30.3 454.0 484.3 30.5 546.5 576.9 
Emgality313.5 102.2 415.7 229.3 23.6 252.9 
Zyprexa28.3 264.5 292.8 41.5 266.2 307.7 
Other Neuroscience81.0 154.0 235.0 53.4 165.7 219.2 
Total Neuroscience453.1 974.7 1,427.8 354.7 1,002.0 1,356.7 
Other:
COVID-19 Antibodies (4)
949.5 226.7 1,176.2— — — 
Forteo330.1 287.7 617.8 386.7 405.2 791.9 
Cialis(3.1)541.8 538.7 64.6 421.6 486.2 
Other96.5 164.3 260.8 144.2 225.2 369.4 
Total Other1,373.0 1,220.5 2,593.5 595.5 1,052.0 1,647.5 
Revenue$11,635.1 $8,683.4 $20,318.5 $9,631.4 $7,468.5 $17,099.8 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(3) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to EUA.
(4) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs.
The following table summarizes revenue by geographical area:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Revenue—to unaffiliated customers (1):
U.S.$3,989.6 $3,161.4 $11,635.1 $9,631.4 
Europe1,098.6 1,046.7 3,629.6 2,984.4 
Japan595.0 660.1 1,832.2 1,919.1 
China400.3 289.1 1,285.0 796.2 
Other foreign countries689.4 583.2 1,936.7 1,768.7 
Revenue$6,772.8 $5,740.6 $20,318.5 $17,099.8 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Schedule of amounts recorded for contract liabilities
The following table summarizes contract liability balances:
 September 30, 2021December 31, 2020
Contract liabilities$278.4 $276.8